Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2) trial platform across Australia and Canada
COGNO is excited to report that the first Canadian participants were recruited to the LUMOS-2 trial in late 2024, marking the first time in COGNO’s 17-year history that we are leading an international platform trial. This milestone reflects a highly successful collaboration between COGNO, the NHMRC CTC (University of Sydney), Omico, the Canadian Cancer Trials Group (CCTG), all trial sites as well as industry partners across all trial arms.
The trial is planned to involve 14 sites in Australia and up to 15 sites in Canada.
